Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.

Is Twitter (TWTR) - Get Report still for sale? That depends on the price, Jim Cramer told his Mad Money viewers Thursday, as he tried to sort out the many rumors surrounding the company everyone loves to hate.

Cramer said the Twitter saga actually began with Microsoft's (MSFT) - Get Report acquisition of LinkedIn (LNKD) . After LinkedIn's stock collapsed in February both Microsoft and (CRM) - Get Report became interested. Once LinkedIn's shares rebounded, Salesforce dropped out of the running. That left Microsoft to seal the deal and made Twitter the only remaining social media company left to acquire.

But now that Twitter's shares have soared to $21 from $14, many of the rumored acquirers are backing away. Shareholders of Salesforce made it abundantly clear that they are not in favor of Salesforce acquiring the ailing Twitter.

Could a marriage for Twitter still happen? Cramer said anything is possible if shares fall low enough, but he doesn't see anything happening until the company reports earnings -- earnings that are likely going to once again be hideous.

Executive Decision: Lew Cirne

For his "Executive Decision" segment, Cramer sat down with Lew Cirne, founder and CEO of New Relic (NEWR) - Get Report , the application monitoring company with a stock that's up 25% since Cramer last checked in just three months ago.

Cirne explained that for a customer like Dunkin Donuts (DNKN) - Get Report , which lets customers pre-order on their smartphones, New Relic provides the dashboards that keep those orders flowing. It's all about making sure the systems are working and the digital experience for customers is at its best.

About 70% of New Relic's revenue stem from application performance monitoring, but Cirne noted that the company just introduced infrastructure monitoring services that greatly increases the addressable market and will allow it to sell even more services to customers.

New Relic last reported 15 customers paying more than $1 million, but Cirne was quick to note they're not stopping there.

Cramer remains a fan of New Relic.

Executive Decision: James Park

In his second "Executive Decision" segment, Cramer once again sat down with James Park, chairman and CEO of Fitbit (FIT) - Get Report , the wearable health and wellness company.

Park said Fitbit is transitioning from a consumer electronics company into a digital health and wellness company, and there have been numerous studies done that prove the impact of Fitbit devices on people's health and well-being. One recent study indicated employees using Fitbits cost employers $1,300 per year in health claims less than those who don't.

When asked how Fitbit compares with the Apple (AAPL) - Get Report Watch, Park said the two are very different companies with a different focus. Fitbit is all about staying healthy and more active and has a global community of users and a strong network effect. Fitbit is a fitness social network, he said, whereas Apple is not.

Park dismissed recent analyst reports that Fitbit's newest devices are seeing sluggish sales. He said that channel checks are not a reliable measure of sell through. He was also bullish on Fitbit's international prospects, which continue to grow.

Cramer admitted that he's been too aggressive on Fitbit historically, but still loves the company and its products.

Executive Decision:

For his third interview, Cramer sat down with Ann Wojcicki, co-founder and CEO of the privately held 23andMe, the only personal genome company approved by the Food and Drug Administration.

Wojcicki said the individual needs a voice in the healthcare process. Consumers want more control and power over their healthcare decisions, which today are often dictated by doctors and health insurers. 23andMe takes a customer's DNA and matches it up against 700,000 data points to produce between 60 to 70 different reports, with more being added all the time.

The FDA is starting to embrace consumer driven healthcare, Wojcicki said, and after patients receive their reports, they're often instructed to follow up with their doctor to discuss what the data means for them and their families.

23andMe is also leading the charge in medical research, taking their treasure trove of data and, with customers' permission, applying it to determine who might or might not respond well to certain drugs or treatments.

Trust remains key, Wojcicki said, and all of 23andMe's customer data is kept separately from their genetic data and customers can both opt in and opt out of research studies as they see fit.

Lightning Round

In the Lightning Round, Cramer was bullish on AMN Healthcare (AHS) , Randgold Resources (GOLD) - Get Report , Hartford Financial Services (HIG) - Get Report , American International Group (AIG) - Get Report , Consolidated Edison (ED) - Get Report and AT&T (T) - Get Report .

Cramer was bearish on Pacific Ethanol (PEIX) - Get Report .

No Huddle Offense

In his "No Huddle Offense" segment, Cramer said in a market that doesn't seem to want to quit going higher, it's worth taking a look at a few reasons why. He said all signs are pointing to Apple's new iPhone being supply constrained, and that's good news for this Action Alerts PLUS stock. Then there's NXP Semiconductor (NXPI) - Get Report , an Action Alerts PLUS holding, which keeps heading higher on takeover rumors, but still trades at less than 15 times earnings.

Cramer was also bullish on Pepsico (PEP) - Get Report , also in Action Alerts PLUS, and Constellation Brands (STZ) - Get Report , whose CEO appeared on last night's show.

With so many good stories in the market, Cramer said it's easy to explain why the averages keep heading higher.

To watch replays of Cramer's video segments, visit the Mad Money page on CNBC.

To sign up for Jim Cramer's free Booyah! newsletter with all of his latest articles and videos please click here.

At the time of publication, Cramer's Action Alerts PLUS had a position in AAPL, NXPI and PEP.